

ARTICLE

Received 8 Mar 2015 | Accepted 4 Jun 2015 | Published 22 Jul 2015

DOI: 10.1038/ncomms8736

OPEN

STAT3 regulated ARF expression suppresses prostate cancer metastasis

Jan Pencik¹, Michaela Schleder^{1,2}, Wolfgang Gruber³, Christine Unger⁴, Steven M. Walker⁵, Athena Chalaris⁶, Isabelle J. Marié^{7,8}, Melanie R. Hassler², Tahereh Javaheri¹, Osman Aksoy², Jaine K. Blayney⁹, Nicole Prutsch², Anna Skucha¹⁰, Merima Herac², Oliver H. Krämer¹¹, Peter Mazal², Florian Grebien¹, Gerda Egger², Valeria Poli¹², Wolfgang Mikulits¹³, Robert Eferl¹³, Harald Esterbauer¹⁴, Richard Kennedy⁵, Falko Fend¹⁵, Marcus Scharpf¹⁵, Martin Braun¹⁶, Sven Perner¹⁶, David E. Levy^{7,8}, Tim Malcolm¹⁷, Suzanne D. Turner¹⁷, Andrea Haitel², Martin Susani², Ali Moazzami¹⁸, Stefan Rose-John⁶, Fritz Aberger³, Olaf Merkel², Richard Morigg^{1,19}, Zoran Culig²⁰, Helmut Dolznig⁴ & Lukas Kenner^{1,2,21}

Prostate cancer (PCa) is the most prevalent cancer in men. Hyperactive STAT3 is thought to be oncogenic in PCa. However, targeting of the IL-6/STAT3 axis in PCa patients has failed to provide therapeutic benefit. Here we show that genetic inactivation of *Stat3* or *IL-6* signalling in a *Pten*-deficient PCa mouse model accelerates cancer progression leading to metastasis. Mechanistically, we identify p19^{ARF} as a direct Stat3 target. Loss of Stat3 signalling disrupts the ARF-Mdm2-p53 tumour suppressor axis bypassing senescence. Strikingly, we also identify *STAT3* and *CDKN2A* mutations in primary human PCa. *STAT3* and *CDKN2A* deletions co-occurred with high frequency in PCa metastases. In accordance, loss of STAT3 and p14^{ARF} expression in patient tumours correlates with increased risk of disease recurrence and metastatic PCa. Thus, STAT3 and ARF may be prognostic markers to stratify high from low risk PCa patients. Our findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition.

¹Ludwig Boltzmann Institute for Cancer Research, Waehringerstrasse 13A, 1090 Vienna, Austria. ²Clinical Institute of Pathology, Medical University of Vienna, 1090 Vienna, Austria. ³Department of Molecular Biology, Paris-Lodron University of Salzburg, 5020 Salzburg, Austria. ⁴Institute of Medical Genetics, Medical University of Vienna, 1090 Vienna, Austria. ⁵Center for Cancer Research and Cell Biology, Queen's University Belfast, BT7 1NN Belfast, UK. ⁶Institute of Biochemistry, University of Kiel, 24098 Kiel, Germany. ⁷Department of Pathology and NYU Cancer Institute, NYU School of Medicine, New York 10016, USA. ⁸Department of Microbiology and NYU Cancer Institute, NYU School of Medicine, New York 10016, USA. ⁹NI Stratified Medicine Research Group, University of Ulster, BT47 6SB Londonderry, UK. ¹⁰CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria. ¹¹Department of Toxicology, University Medical Center, 55131 Mainz, Germany. ¹²Molecular Biotechnology Center (MBC), Department of Genetics, Biology and Biochemistry, University of Turin, Turin 10126, Italy. ¹³Department of Medicine I, Division: Institute for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria. ¹⁴Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria. ¹⁵Institute of Pathology and Neuropathology, University Hospital Tuebingen, 72076 Tuebingen, Germany. ¹⁶Institute of Pathology, Center for Integrated Oncology Cologne/Bonn, University Hospital of Bonn, 53127 Bonn, Germany. ¹⁷Department of Pathology, University of Cambridge, CB2 0QQ Cambridge, UK. ¹⁸Department of Chemistry and Biotechnology, Swedish University of Agricultural Sciences, 75007 Uppsala, Sweden. ¹⁹Unit for Translational Methods in Cancer Research, University of Veterinary Medicine Vienna, 1210 Vienna, Austria. ²⁰Department of Urology, Medical University of Innsbruck, 6020 Innsbruck, Austria. ²¹Unit of Pathology of Laboratory Animals (UPLA), University of Veterinary Medicine Vienna, 1210 Vienna, Austria. Correspondence and requests for materials should be addressed to L.K. (email: lukas.kenner@meduniwien.ac.at).

PCa is the second most frequently diagnosed cancer in men with >200,000 new cases reported in the USA annually¹. Screening for the sensitive yet diagnostically unspecific biomarker prostate-specific antigen (PSA) has led to a substantial rise in the diagnosis of early stage PCa². The failure of current diagnostic tools to reliably distinguish non-aggressive tumours from aggressive ones to predict therapeutic response³ urgently calls for the identification of better biomarkers to guide treatment. Furthermore, there is need for novel targeted therapies of metastatic PCa based on a better molecular understanding of the disease⁴. The lack of markers to stratify PCa cases into low- and high-risk groups results in overtreatment of 20–42% of patients⁵. STAT3, the major downstream mediator of IL-6 signalling, was shown to be related to advanced tumour growth, by tumour-autonomous mechanisms and by modulating tumour-associated stroma⁶. Although STAT3 activation is observed in ~50% of PCa⁷ its functional role in tumorigenesis and metastasis has not been elucidated. Data from the majority of human PCa cancer cell lines support an oncogenic and growth promoting role of IL-6 and STAT3 *in vitro*⁸. However, metastatic LNCaP cells were growth inhibited *in vitro* and *in vivo* in response to IL-6 treatment⁸. Moreover, treatment of patients with an IL-6 blocking antibody did not result in a survival advantage in patients with advanced PCa⁹. Thus, addressing the precise *in vivo* role of IL-6/STAT3 in PCa is of utmost importance to reassess diagnostic and therapeutic approaches.

PTEN is one of the most frequently deleted or mutated tumour suppressors in PCa, with an estimated incidence of 70% in metastatic PCa, causing aberrant activation of the PI3K-AKT-mTOR signalling pathway¹⁰. Loss of *Pten* leads to senescence, which is critically regulated by the ARF-p53 pathway¹¹. While the tumour suppressor ARF (p14^{ARF} in humans; p19^{ARF} in mice) is readily degraded in normal cells, it is stabilized to increase p53 function on loss of Pten. ARF was shown to augment p53 stability by promoting the degradation of Mdm2, a negative regulator of p53. Concomitant inactivation of *Pten* and *p53* leads to bypass of senescence and as a consequence to a malignant PCa phenotype¹¹. Previous studies report PTEN-STAT3 signalling crosstalk in malignant glioblastoma¹², but the detailed molecular mechanisms in cancer progression and metastasis remain unresolved.

In this study, we show that loss of IL-6/Stat3 signalling in a *Pten*-deficient PCa model accelerates cancer progression leading to metastasis. Loss of IL-6/Stat3 signalling in PCa bypasses senescence via disrupting the ARF-Mdm2-p53 tumour suppressor axis. We identify ARF as a novel direct Stat3 target. Notably, loss of STAT3 and p14^{ARF} expression correlates with increased risk of recurrence in PCa patients. In addition, STAT3 and p14^{ARF} expression was lost in metastasis compared with the primary tumours. We identified *STAT3* and *CDKN2A* mutations in primary PCa patients. Furthermore, PCa metastases show a high frequency of *STAT3* and *CDKN2A* deletions. We propose *STAT3* and *ARF* as prognostic markers for high versus low risk PCa patient stratification.

Results

Co-deletion of *Stat3* and *Pten* triggers PCa. To study the role of PTEN and STAT3 in PCa development, we took advantage of mice with conditional loss of *Pten* in the prostate epithelium (*Pb-Cre4 Pten^{fl/fl}*) hereafter referred to as *Pten^{pc-/-}* (ref. 13). Stat3 protein levels were markedly induced in *Pten^{pc-/-}* compared with wild-type (WT) prostate epithelium (Fig. 1a,b). *Pten^{pc-/-}* tumours showed strong Akt Ser473 phosphorylation and, unexpectedly, Stat3 Tyr705 and Ser727 phosphorylation suggesting maximal transcriptional activity of Stat3 (Fig. 1a,b and Supplementary Fig. 1a). In addition, we observed an increase in

IL-6R α levels in tumour cells and soluble IL-6R serum levels (Supplementary Fig. 1a–c) as well as increased *Stat3*, *IL-6R α* and *IL-6* mRNA levels (Supplementary Fig. 1d) in *Pten^{pc-/-}* PCa compared with WT controls. To prove that loss of Stat3 signalling influences PCa formation, we generated mice with concomitant loss of *Pten* and *Stat3* in prostate epithelial cells. Prostate-specific deletion of *Pten* and *Stat3* was confirmed by PCR (Supplementary Fig. 2a). Immunohistochemistry (IHC) analysis confirmed loss of pY-Stat3 and Stat3 in *Pten^{pc-/-} Stat3^{pc-/-}* tumour cells (Supplementary Fig. 2b), while still being present in stromal cells (Supplementary Fig. 2c). Surprisingly, and in sharp contrast to the oncogenic role of Stat3 in many cancers^{14,15}, *Pten^{pc-/-} Stat3^{pc-/-}* mice showed accelerated PCa formation with up to sixfold increase in tumour weight compared with *Pten^{pc-/-}* tumours at different stages of PCa development (Fig. 1c,d and Supplementary Fig. 2d,e). *Pten^{pc-/-} Stat3^{pc-/-}* tumours showed increased numbers of Ki-67 positive (Ki-67⁺) proliferating cells and reduced numbers of cleaved caspase 3 positive (CC3⁺) apoptotic cells compared with *Pten^{pc-/-}* prostates (Fig. 1e,f).

Compared with *Pten^{pc-/-}* mice¹⁶, *Pten^{pc-/-} Stat3^{pc-/-}* mice displayed a significantly reduced median survival (Fig. 1g). Intriguingly, *Pten^{pc-/-} Stat3^{pc-/-}* mice developed high-grade (poorly differentiated) PCa with liver and lung metastases (Fig. 2a). Histopathological analysis of PCa-bearing animals revealed widespread metastasis in 75% of *Pten^{pc-/-} Stat3^{pc-/-}* mice. By contrast, *Pten^{pc-/-}* mice only showed local invasion into seminal vesicles and never developed distant metastases (Fig. 2b and Supplementary Table 1). Furthermore, loss of Stat3 promoted PCa formation in *Pten* heterozygous prostate tissue (*Pten^{pc+/-} Stat3^{pc-/-}*) at 19 weeks of age, whereas *Pten^{pc+/-}* mice developed only prostatic intraepithelial neoplasia¹⁷ (PIN) (Supplementary Fig. 3a). Our data demonstrate that Stat3 suppresses malignant progression of *Pten*-deficient PCa. We found reduced p53 protein expression in *Pten^{pc+/-} Stat3^{pc-/-}* prostates (Supplementary Fig. 3b). *Pten* heterozygosity alone had no effect on p53 expression as demonstrated before¹¹. Interestingly, prostate-specific loss of *Stat3* (*Stat3^{pc-/-}*) led to development of PIN lesions in prostates at 19 weeks of age (Supplementary Fig. 3c). Analysis of consecutive sections revealed invasive regions and high-grade PIN in *Pten^{pc-/-}* mice at 19 weeks of age, whereas *Pten^{pc-/-} Stat3^{pc-/-}* mice showed early progression to poorly differentiated adenocarcinoma (Fig. 2c). At 52 weeks of age *Pten^{pc-/-} Stat3^{pc-/-}* tumours had developed into poorly differentiated carcinomas with 86% penetrance compared with *Pten^{pc-/-}* tumours, which showed only signs of focal invasion and late adenocarcinoma formation (Fig. 2d). Notably, *Pten^{pc-/-}* tumour cells uniformly expressed nuclear Stat3 at 19 weeks of age (Fig. 2e), whereas more advanced tumours at 52 weeks of age showed profoundly reduced nuclear Stat3 expression (Fig. 2e,f), suggesting that Stat3 expression decreased during PCa progression.

To further dissect the tumour promoting effects of loss of Stat3, we established primary mouse *Pten^{-/-}* PCa cells with stable, short hairpin RNA (shRNA) mediated knockdown of *Stat3*. Western blot and IHC analyses confirmed efficient Stat3 knockdown in these cells (Fig. 3a and Supplementary Fig. 4a). In line with our genetic data, *Pten^{-/-}* mouse PCa cells with shStat3 knockdown were significantly more invasive in a transwell invasion assay compared with control cells (Fig. 3b). We verified the aggressive behaviour of *PTEN-STAT3* double deficient tumour cells in an organotypic, physiologically relevant *in vitro* three-dimensional cancer model¹⁸. *Pten^{-/-}-shStat3* PCa cells displayed a more invasive phenotype compared with control cells in organotypic assays (Fig. 3c and Supplementary Fig. 4b). In addition, *Pten^{-/-}-shStat3* cells showed increased




Figure 1 | Genetic deletion of *Stat3* and *Pten* triggers progressive prostate tumorigenesis and lethal disease. (a) Comparison of prostates from WT and *Pten^{PC-/-}* mice at 19 weeks of age using immunohistochemical (IHC) analysis of pY-Stat3, pS-Stat3 and Stat3. Scale bars, 100 μm. (b) Protein expression analysis of pY-Stat3, pS-Stat3, Stat3, p-Akt, Akt and β-actin with western blots in 19-week-old prostates from WT and *Pten^{PC-/-}* mice. (c) Gross anatomy of representative prostates isolated at 52 weeks of age from WT, *Stat3^{PC-/-}*, *Pten^{PC-/-}* and *Pten^{PC-/-} Stat3^{PC-/-}* mice. Scale bars, 10 mm. (d) Prostate weights of 52-week-old WT, *Stat3^{PC-/-}*, *Pten^{PC-/-}* and *Pten^{PC-/-} Stat3^{PC-/-}* mice (n = 24). Mean values are shown; data were analysed by one-way analysis of variance with Tukey’s multiple comparison test; error bars: s.d. (e) IHC analyses of prostates from 19-week-old WT, *Stat3^{PC-/-}*, *Pten^{PC-/-}* and *Pten^{PC-/-} Stat3^{PC-/-}* mice stained for Ki-67 and cleaved caspase 3 (CC3). Scale bars, 100 μm; insets: × 600 magnification. (f) Quantification of cells positive for Ki-67 and CC3 using HistoQuest software (n = 5). Data were analysed by Student’s *t*-test and are shown as mean ± s.d. (g) Kaplan-Meier cumulative survival analysis revealed a significant (P < 0.0001; log-rank test) decrease in lifespan of *Pten^{PC-/-} Stat3^{PC-/-}* compared with *Pten^{PC-/-}* mice (n = 49); WT and *Stat3^{PC-/-}* mice served as controls.

anchorage-independent cell growth in soft agar compared with *Pten^{-/-}* PCa cells expressing non-targeting shRNA (control shRNA) (Fig. 3d). To corroborate our findings in human cells, combined knockdown of STAT3 and PTEN in human RWPE-1 prostate cells (Fig. 3e) increased invasiveness in organotypic assay compared with control and single knockdown cells (Fig. 3f,g).

Notably, re-expression of STAT3 in human PC3 prostate carcinoma cells, which lack STAT3 expression (Supplementary Fig. 4c), led to significantly decreased cell numbers and reduced foci formation (Fig. 3h and Supplementary Fig. 4d,e). These data are consistent with a cell-autonomous tumour suppressive role of Stat3 in PCa.




Figure 2 | Co-deletion of *Stat3* and *Pten* enhances prostate cancer transformation and metastatic potential. (a) Histopathological analysis of primary PCa, livers and lungs at 52 weeks of age from WT, *Pten*^{PC-/-} and *Pten*^{PC-/-} *Stat3*^{PC-/-} mice. The dashed red lines encircle areas of advanced liver or lung metastases (M), which are surrounded by normal liver (Li) or normal lung (Lu), respectively. Scale bars, 100 μ m; insets: \times 600 magnification. (b) Percentage of mice with sites of distant PCA metastases ($n = 49$). (c) Summary of the histological findings of mouse prostates examined at 19 weeks postpartum (p.p.) from WT, *Stat3*^{PC-/-}, *Pten*^{PC-/-} and *Pten*^{PC-/-} *Stat3*^{PC-/-} mice. (d) Summary of the histological findings of mouse prostates examined at 52 weeks p.p. from WT, *Stat3*^{PC-/-}, *Pten*^{PC-/-} and *Pten*^{PC-/-} *Stat3*^{PC-/-} mice. Histological grading and classification of mouse prostates was done according to Chen *et al.*⁶⁷ (e) Stat3 IHC in 19-week- and 52-week-old *Pten*^{PC-/-} prostate tumours. Scale bars, 100 μ m. (f) Quantification of Stat3 staining in 19-week- and 52-week-old *Pten*^{PC-/-} prostate tumours using HistoQuest software, $P < 0.0001$. Data were analysed by Student's *t*-test and are shown as mean \pm s.d. ($n = 5$).

Stat3 regulates the ARF–Mdm2–p53 pathway. Since loss of *Pten* triggers senescence thereby restricting cancer progression and metastasis¹¹, we next tested whether Stat3 exerts a tumour suppressive function by activating senescence-inducing programmes in *Pten*^{PC-/-} PCa cells¹⁹ at an early stage of PCa development (19 weeks). Senescence is generally characterized by upregulation of p53, cyclin-dependent kinase inhibitor 1 (Cdkn1, p21), promyelocytic leukaemia protein (PML) and elevated senescence-associated- β -galactosidase activity²⁰. Of note, *Pten*^{PC-/-} *Stat3*^{-/-} tumours lacked p21 expression, displayed reduced numbers of PML nuclear bodies and decreased SA- β -Gal activity compared with *Pten*^{PC-/-} tumours (Fig. 4a,b and Supplementary Fig. 5a,b), suggesting Stat3 as a novel

mediator of senescence in response to loss of *Pten*. Senescence associated with loss of *Pten* was shown to be bypassed by deletion of p53 leading to early lethality¹¹. We show here that loss of Stat3 and *Pten* revealed a phenotype strikingly similar to that of p53 and *Pten* loss¹¹. Intriguingly, Stat3 and *Pten* deletion resulted in downregulation of p53 expression in the prostate epithelium, which was accompanied by the loss of p19^{ARF} (Fig. 4a,b). The p53 expression in the tumour stromal cells remained unchanged (Supplementary Fig. 5c). Since p19^{ARF} is a critical regulator of Mdm2 degradation²¹, our results suggest that the tumour suppressive capacity of Stat3 in senescent tumour cells²² may rely on the p19^{ARF}–Mdm2–p53 tumour suppressor axis.




Figure 3 | Stat3 suppresses colony formation and invasion. (a) shRNA-mediated knockdown of Stat3 in *Pten*^{-/-} mouse PCa cells leads to robust decrease of Stat3 levels as demonstrated by western blotting. In all knockdown experiments, scrambled non-target shRNA served as a control (control shRNA/shcontrol). (b) Representative histology of increased matrigel invasion after shRNA-mediated knockdown of Stat3 in *Pten*-deficient (*Pten*^{-/-}) mouse PCa cells. Quantification of relative invasion is shown ($n = 3$). Scale bars, 100 μm . (c) Organotypic culture assays of *Pten*^{-/-} mouse PCa cells in the absence of Stat3 showed capacity to invade into the fibroblast containing collagen gel (red arrows). Scale bars, 50 μm . The invasive area/total tumour cell area was quantified (control shRNA, $n = 4$, shStat3 $n = 3$). (d) Soft agar colony formation of primary *Pten*^{-/-} mouse PCa cells with shStat3 and controls was quantified ($n = 3$). Scale bars, 200 μm . Data were analysed by Student's *t*-test and are shown in **c–e** as mean \pm s.d. (e) Efficient STAT3 and PTEN siRNA-mediated knockdown of RWPE-1 cells was demonstrated by western blot. Scrambled non-target siRNA served as a control (control siRNA/siControl) (f) Organotypic culture of RWPE-1 cells in the presence and absence of STAT3 and/or PTEN cocultivated in contact with human prostate stromal fibroblasts seeded in collagen I gels after 8 days of culture. Representative H&E stainings are shown, red arrows indicate invasion, scale bars, 100 μm . ($n = 3$). (g) Quantification of invasion of RWPE-1 cells knocked down for PTEN and/or STAT3 using siRNA (number of invasive cells per mm, $n = 5$ sections for each condition). Data were analysed by one-way analysis of variance with Tukey's multiple comparison test; error bars: s.d. (h) Crystal violet stains of focus formation of STAT3-V5 and empty vector transduced PC3 cells after 4 days of incubation (Supplementary Fig. 4c–e).

Recently, co-inactivation of p53 and ARF was linked to human triple-negative breast cancer progression through IFN β -STAT1-ISG15 signalling²³. Interestingly, ISG15 and Stat3 protein expression levels paralleled each other in the PCa mouse models (Supplementary Fig. 6a). This suggests an altered ISGylation system, which could be independent of androgen receptor expression²⁴ (Supplementary Fig. 6b). It is noteworthy, that numerous AR-positive tumour cells were observed in the metastases of the *Pten*^{pc-/-}*Stat3*^{pc-/-} PCa mouse models (Supplementary Fig. 6c), underlining the relevance of our model to human PCa²⁵. Molecular pathological analysis confirmed AR-positive tumour nodules in five out of five cases of lung metastases consist of 66% AR-positive cells (Supplementary Fig. 6d).

Mechanistically, Pten was shown to block PI3K-mediated translocation of Mdm2 into the nucleus, where it promotes rapid degradation of p53 (ref. 26). In line with the published function of PML to increase p53 stability by sequestering Mdm2 to the nucleolus, disruption of *Pten* and *Stat3* resulted in increased Mdm2 protein levels (Fig. 4b). Therefore, loss of *Stat3* promotes PCa development by bypassing senescence regulated by the p19^{ARF}-p53 axis. We therefore hypothesize that Stat3 may act through ARF as an important gatekeeper controlling senescence counteracting metastasis, which we tested further.

Immunoblot and IHC analyses revealed a positive correlation between Stat3 and p19^{ARF} levels. Moreover, loss of Stat3 led to a profound decrease in p19^{ARF} protein (Fig. 4a,b). Transcript levels of the well-established Stat3 target genes *Socs3* and *c-fos*²⁷




Figure 4 | Stat3 is a critical regulator of the ARF-Mdm2-p53 tumour suppressor pathway and senescence. (a) Haematoxylin/eosin (H&E) stains show higher grade Pca in *Pten^{pc-/-} Stat3^{pc-/-}* mice compared with *Pten^{pc-/-}* mice. Scale bars, 100 μ m. IHC analysis of p53, p19^{ARF} and staining for senescence-associated- β -galactosidase activity in prostates from 19-week-old WT, *Pten^{pc-/-}* and *Pten^{pc-/-} Stat3^{pc-/-}* mice. Scale bars, 100 μ m; insets: $\times 600$ magnification. (b) Western blot analysis showing pY-Stat3, Stat3, p53, p19^{ARF}, Mdm2 and PML expression levels in *Pten^{pc-/-} Stat3^{pc-/-}* compared with *Pten^{pc-/-}* mice. β -actin serves as a loading control. The remaining Stat3 bands in *Pten^{pc-/-} Stat3^{pc-/-}* prostates are due to Stat3 stromal expression (Supplementary Fig. 2c). (c) Western blot analysis of Stat3 and p19^{ARF} expression in prostates of 19-week-old WT or *Stat3^{pc-/-}* mice. β -actin serves as a loading control. (d) qRT-PCR analysis of *Stat3* and *p19^{ARF}* mRNA expression in prostates of 19-week-old WT or *Stat3^{pc-/-}* mice ($n=5$ each). Data were analysed by Student's *t*-test and are shown as mean \pm s.d. (e) Western blot analysis of Stat3 and p19^{ARF} expression in WT, *Stat3^{C/+}* or *Stat3^{C/C}* MEFs. (f) qRT-PCR analysis of *Stat3* and *p19^{ARF}* transcript levels in WT, *Stat3^{C/+}* and *Stat3^{C/C}* MEFs ($n=3$ each). Data were analysed by Student's *t*-test and are shown as mean \pm s.d. (g) *In vivo* ChIP analysis of Stat3 binding to *p19^{ARF}* and *Socs3* promoters, respectively, in WT and *Stat3^{pc-/-}* prostate tissue. Stat3 binding to the *Socs3* (ref. 69) promoter, which is a direct Stat3 target served as a positive control. Data were normalized to Cis4200, which served as the negative control⁷⁰. (h) *In vivo* ChIP analysis of Stat3 binding to the *p19^{ARF}* and *Socs3* promoters in Pca. Note the >15 -fold enrichment of Stat3 bound to promoter fragments in *Pten^{pc-/-}* compared with *Pten^{pc-/-} Stat3^{pc-/-}* tumours. Data in g and h were analysed by one-way analysis of variance with Tukey's multiple comparison test and shown as mean \pm s.d. (Primer pairs are listed in Supplementary Table 2).

paralleled p19^{ARF} expression in WT, *Pten^{pc-/-}* and *Pten^{pc-/-} Stat3^{pc-/-}* prostate tissue (Supplementary Fig. 7a,b). *Stat3^{pc-/-}* prostates displayed a significant decrease

in p19^{ARF} protein and mRNA levels compared with WT controls (Fig. 4c,d), suggesting direct regulation of p19^{ARF} expression by Stat3. We first tested this by analysing p19^{ARF} expression in

passage-matched homozygous *Stat3* knockout (*Stat3*^{KO}) and WT mouse embryonic fibroblasts (MEFs). Both p19^{ARF} protein and mRNA levels were significantly reduced in the absence of *Stat3* (Supplementary Fig. 7c,d). Consistently, MEFs expressing one or two hyperactive *Stat3* alleles (*Stat3*^{C/+} and *Stat3*^{C/C}) from the endogenous *Stat3* locus²⁸ displayed upregulation of p19^{ARF} protein and mRNA (Fig. 4e,f). *In silico* analysis of the p19^{ARF} promoter²⁹ predicted two potential *Stat3*-binding sites (Supplementary Fig. 7e). Chromatin immunoprecipitation (ChIP) experiments showed approximately threefold increase in *Stat3*-binding activity to the proximal p19^{ARF} promoter region in WT compared with *Stat3*^{Pc-/-} prostate tissue (Fig. 4g). We next wanted to know if *Stat3* binding was further elevated in *Pten*-deficient tumours since *Pten* loss increased ARF expression. By performing ChIP in *Pten*^{Pc-/-} primary mouse prostate tumours, we demonstrated a 15-fold increase of *Stat3* binding to the p19^{ARF} promoter (Fig. 4h), which was abrogated in *Pten*^{Pc-/-}*Stat3*^{Pc-/-} tumours. These data identify p19^{ARF} as a novel *Stat3* target gene.

Loss of *IL-6* and *Pten* leads to cancer and metastasis. *IL-6* signalling is the major regulator of *Stat3* with therapeutic relevance. To address whether *Stat3* activation in *Pten*^{Pc-/-} mice depends on *IL-6* signalling, we crossed *Pten*^{Pc-/-} mice with *IL-6*^{-/-} mice³⁰. Co-deletion of *IL-6* and *Pten* triggered early lethality (Fig. 5a), progressive high-grade adenocarcinoma formation with increased tumour growth and weight (Fig. 5b,c), resulting in disseminated metastases (Fig. 5d), for example, in the liver (Supplementary Fig. 8a). Loss of *IL-6* in *Pten* heterozygous prostate tissue also resulted in high-grade invasive PCa with metastasis formation at 15 months of age (Supplementary Fig. 8b). Like *Pten*^{Pc-/-}*Stat3*^{Pc-/-} mice, *Pten*^{Pc-/-}*IL-6*^{-/-} mice showed markedly enhanced PCa growth (Supplementary Fig. 8c,d) at 19 weeks of age, increased Ki-67⁺ but decreased CC3⁺ expression levels compared with *Pten*^{Pc-/-} prostates (Fig. 5e-g). IHC analysis revealed absence of pY-*Stat3* and *Stat3* expression in *Pten*^{Pc-/-}*IL-6*^{-/-} tumours (Supplementary Fig. 8e).

Intriguingly, *in vivo* blocking of *IL-6*/*Stat3* signalling by the JAK1/2 inhibitor ruxolitinib in human LNCaP xenografts showed significantly enhanced tumour size and weight (Fig. 6a,b). The ruxolitinib-treated xenografts also had markedly increased numbers of Ki-67⁺ cancer cells accompanied by a decrease in *Stat3* and p14^{ARF} expression (Fig. 6c). Moreover, ruxolitinib treatment of LNCaP cells significantly promoted colony formation (Fig. 6d). Of note, LNCaP cells lack JAK1 expression and do not respond to interferon signalling³¹. Moreover, *Stat3* was shown to be activated in xenografts of LNCaP cells, most likely due to the sole action of JAK2 (refs 32,33). Ruxolitinib is a dual-specific JAK1/2 kinase inhibitor and therefore, effects of ruxolitinib on the LNCaP xenograft model are likely to be a consequence of JAK2/*Stat3* inhibition independent of IFN gamma signalling.

Loss of *STAT3* and ARF in PCa is associated with metastases. The fact that activated *Stat3* induces its own transcription³⁴ led us to measure *IL-6* and *Stat3* mRNA levels in primary human tumours and to correlate them with clinical outcome. Using the Taylor gene expression profiling data set (GSE21032)³⁵, we dichotomized samples based on the *z*-scores of *IL-6* or *Stat3* expression. Specifically for *IL-6* expression, samples that had *z*-scores < -2 were defined as low *IL-6* and all others (*z*-scores > -2) were used as a comparator for prognostic significance. Conversely, samples that had *Stat3* *z*-scores > 2 were defined as *Stat3* high and all other samples (*z*-scores < 2) were used as comparators. Time to biochemical recurrence (BCR) was assessed as an indicator of individual prognosis. BCR was

defined by an increase to >0.2 ng ml⁻¹ PSA in serum. Of note, patients with low *IL-6* expression levels showed a significantly higher risk of BCR compared with patients with high *IL-6* expression (Fig. 7a). In line, patients with high *Stat3* mRNA levels demonstrate good prognosis. This may reflect a higher level of senescence competence compared with patients with lower *Stat3* mRNA levels (Fig. 7b).

We next tested whether expression of *Stat3* and p14^{ARF} can serve as novel prognostic markers predicting the risk of BCR and metastatic disease progression. *Stat3* and p14^{ARF} levels were independently evaluated by five pathologists in 204 human PCa specimens from patients who underwent radical prostatectomy. Patient samples were categorized into low or high expression groups based on staining intensities and number of positive cells (Methods) using validated antibodies (Supplementary Fig. 9a,b). Classification was verified by quantitative histopathological image analysis³⁶ (Supplementary Fig. 10a). Indeed, increased Gleason score (GSC) correlated with low *Stat3* or p14^{ARF} protein expression levels. In addition, we found a strong direct correlation between *Stat3* and p14^{ARF} in accordance with p14^{ARF} being a direct target of *Stat3* (Fig. 7c,d). *Stat3* expression was significantly decreased in PCa (GCS ≤ 7) compared with PIN areas of 67 matched patient samples (Supplementary Fig. 10b,c). Strikingly, both low *Stat3* expression (*P* < 0.007; log-rank test) and low p14^{ARF} (*P* < 0.000001; log-rank test) expression were associated with poor outcome (Fig. 7e,f). Moreover, combined loss of p14^{ARF} and *Stat3* expression in tumours of PCa patients predicted the worst outcome (*P* = 0.000007, log-rank test) (Fig. 7g). Using multivariate analysis, we identified p14^{ARF} as a reliable, independent prognostic marker for PCa, which has a twofold higher hazard ratio compared with GSC (Fig. 7h). In accordance with the literature^{25,37}, we found increased ARF expression in metastases compared with primary human PCa (Supplementary Fig. 11a,b). IHC analysis of matched primary and metastatic human PCa revealed significant loss of PTEN expression in metastatic PCa (Fig. 8a and Supplementary Fig. 11c), suggesting an important role of PTEN loss in PCa metastasis. PTEN levels showed no significant correlation with *Stat3* or p14^{ARF} protein expression in a cohort of > 200 patients (Supplementary Fig. 11d,e). Moreover, we demonstrated that loss of *Stat3* and/or p14^{ARF} is associated with progression to metastatic disease (Fig. 8b-d). This is supported by expression data from matched primary and metastatic PCa samples (Supplementary Fig. 12a-c), where in all seven cases a significant loss of *Stat3* and p14^{ARF} expression occurred in the metastases.

Current data suggest that PCa harbour common genomic and epigenomic alterations^{38,39}. We analysed large-scale human cancer data sets (International Cancer Genome Consortium (ICGC) and COSMIC databases) and the GEO methylation database⁴⁰. Surprisingly, we found mutations of *Stat3* (2.5%) and *CDKN2A* (2.3%) in a cohort of 529 patients with primary PCa (Fig. 8e). We found five missense-, one nonsense- and several conservative *Stat3* mutations in primary PCa patients (Supplementary Fig. 13a). *Stat3* and/or *CDKN2A* were frequently deleted in metastatic PCa (Fig. 8f and Supplementary Fig. 13b), which have been confirmed in an independent data set³⁵ (Fig. 8g). Notably, in 66% of *Stat3* deletions, PTEN was co-deleted in both metastases data sets investigated (Fig. 8f,g). However, we neither detected human *IL-6* mutations nor methylation of *Stat3* and *CDKN2A* loci in primary and metastatic PCa (Supplementary Figs 13c,d and Supplementary Figs 14a,b).

Discussion

Due to the lack of prognostic markers for risk stratification, many PCa patients suffer from overtreatment and a severely reduced quality-of-life. Understanding the molecular genetics underlying




Figure 5 | Deletion of *IL-6* and *Pten* triggers progressive prostate tumorigenesis and metastatic disease. (a) Kaplan-Meier cumulative survival analysis of *Pten*^{PC-/-}*IL-6*^{-/-} compared with *Pten*^{PC-/-} mice; WT and *IL-6*^{-/-} mice served as controls ($P < 0.0001$; log-rank test). (b) Gross anatomy of representative prostates isolated at 38 weeks of age from WT, *IL-6*^{-/-}, *Pten*^{PC-/-} and *Pten*^{PC-/-}*IL-6*^{-/-} mice. Scale bars, 10 mm. (c) Prostate weights of 38-week-old WT, *IL-6*^{-/-}, *Pten*^{PC-/-} and *Pten*^{PC-/-}*IL-6*^{-/-} mice. Mean values are shown; error bars: s.d. ($n = 43$). (d) Histopathological analysis of haematoxylin/eosin-stained primary PCA and liver at 38 weeks of age from WT, *IL-6*^{-/-}, *Pten*^{PC-/-} and *Pten*^{PC-/-}*IL-6*^{-/-} mice. Arrowhead in the inset: area of nerve sheath infiltration. Scale bars, 100 μ m. (e) IHC analysis of Ki-67 and CC3 in prostates from 19-week-old WT, *IL-6*^{-/-}, *Pten*^{PC-/-} and *Pten*^{PC-/-}*IL-6*^{-/-} mice. Scale bars, 100 μ m. (f,g) Bar graphs indicate percentage of cells positive for Ki-67 and CC3 (e). Protein levels quantification was done with HistoQuest software ($n = 5$). Data from c, f and g were analysed by Student's *t*-test and are shown as mean \pm s.d.

PCa and the identification of genetic and/or biochemical markers predicting clinical outcome is therefore of high priority.

Our data reveal robust upregulation of the *IL-6*/Stat3 signalling axis in a PCa mouse model as well as in patient specimens. Loss of *Stat3* or *IL-6* accelerates the progression to metastatic PCa; this stands in sharp contrast to the proposed oncogenic function of *IL-6*/Stat3 signalling in PCa^{33,41,42}. Moreover, there are contradictory studies on the role of senescence in tumorigenesis^{42–44}. Whether these different findings are due to

the use of distinct mouse models, strains and species remains to be addressed. Here we combine an array of experimental approaches including *in vivo* models, mechanistic data with comprehensive human pathological, molecular and genetic data to underscore the tumour suppressive role of STAT3 (ref. 45). Thereby we identify STAT3 and its transcriptional target ARF as novel powerful prognostic markers for PCa patients. In PCa and several other cancers, elevated serum *IL-6* levels correlate with a poor prognostic outcome for patients⁴⁶. This sparked the




Figure 6 | JAK1/2 inhibition promotes tumour progression and decreases STAT3 and p14^{ARF} expression. (a) Gross anatomy of representative LNCaP xenograft tumours treated with ruxolitinib. Mice bearing xenografts were treated with a vehicle or 50 mg kg⁻¹ ruxolitinib. Scale bars, 10 mm. (b) Tumour weight of vehicle-treated mice versus ruxolitinib treatment for 22 days of age-matched SCID beige mice. Mean values are shown; error bars: s.d. ($n = 3$). (c) IHC stainings of Ki-67, STAT3 and p14^{ARF} expression in vehicle versus ruxolitinib-treated xenografted tumours ($n = 3$), scale bar 50 μ m. (d) LNCaP cells treated with control (DMSO) or 10 μ M ruxolitinib were grown in soft agar for 12 days. Mean values are shown; error bars: s.d. ($n = 4$). Data from **b** and **d** were analysed by Student's *t*-test.

development of IL-6 inhibitors to abrogate hyperactive IL-6/STAT3 signalling. However, blocking IL-6/STAT3 signalling was ineffective in patients with advanced PCa^{9,47}, challenging this oncogenic concept.

We show that loss of Stat3 accelerates malignant progression of prostate tumours through abrogation of p19^{ARF} expression, which we identified as a novel direct Stat3 target gene. Several reports have demonstrated that loss of *Pten* leads to increased senescence associated with p53 stabilization triggered by p19^{ARF} (refs 11,48). Inactivation of *Stat3* and *Pten* revealed striking similarities to the malignant phenotype observed after deletion of *Pten* and *p53* (ref. 11). Our model implicates high Stat3 and/or IL-6 levels in senescence-competent PCa and therefore does not contradict the general observation of high IL-6 and/or Stat3 expression in many cancers. We show that impaired p19^{ARF} expression in *Stat3*-deficient PCa is accompanied by loss of senescence. In line with our data, concomitant loss of *Pten* and p19^{ARF} in MEFs resulted in bypass of senescence, induction of hyperproliferation and oncogenic transformation¹¹. Accordingly, overexpression of p19^{ARF} leads to p53-dependent cell growth arrest and induces senescence⁴⁹. However, systemic p19^{ARF} deficiency in *Pten*^{Pc-/-} mice did not accelerate PCa or enhance p53 accumulation⁵⁰, which might be explained by inflammatory cytokines and/or growth factors produced by the multiple tumours developing in other organs⁵¹. Here we identified an unpredicted tumour suppressor role for Stat3 signalling in PCa by its ability to control the tumour suppressor ARF–Mdm2–p53 pathway in a context-dependent manner. Therefore, we propose the STAT3–ARF axis as a previously unknown safeguard mechanism against malignant progression in PCa. Importantly we also demonstrate that loss or inhibition of STAT3–ARF signalling enables tumour progression and metastasis formation. This is reflected in patients with PCa, since loss of STAT3 and/or p14^{ARF} expression significantly correlates with poor prognosis in large independent data sets. Therefore, our study identifies STAT3 and ARF as potential novel prognostic markers predicting BCR-free survival. The importance of the STAT3–ARF axis is corroborated by the presence of *STAT3* mutations in primary PCa and frequent deletions of *STAT3* and *ARF* in metastatic PCa. The significant loss of STAT3 and p14^{ARF} expression from matched primary and metastatic PCa samples underlines the relevance of our findings.

Interestingly, loss of PTEN expression in primary human PCa did not correlate with overall survival⁵² and could not predict PCa-specific death⁵³. Moreover, heterozygous PTEN deletions far outnumber homozygous deletions in primary human PCa⁵⁴ and we show here that PTEN is mutated or lost only in a small subset (4.7%) of a large cohort of patients with primary PCa. However, PTEN is lost in >50% of human PCa metastases^{55,35}, suggesting an important role for PTEN in this process. Finally, we show in our study that STAT3 is co-deleted with PTEN in 66% of human PCa metastases in two independent data sets. Since PTEN is mutated or lost in only a minor fraction of primary PCa, other aberrations must occur (oncogene induction or loss of tumour suppressor function) to activate STAT3 and ARF to induce senescence in human cancers. Indeed, several studies indicate that different aberrations can lead to induction of senescence in human cancers^{48,56}.

Many human PCa cases are diagnosed with low GSCs, which are of clinical low risk. Only a minority of these tumours will progress to aggressive lethal PCa. We show that ARF is an independent prognostic marker with a twofold higher hazard ratio compared with GSC (Fig. 7h). This will enable significantly improved stratification of low risk PCa patients into active surveillance, avoiding severe side effects such as incontinence and/or impotence. Together with a previously defined four-gene




Figure 7 | Loss of STAT3 and/or p14^{ARF} expression predicts early BCR in patients with PCa. (a,b) Kaplan-Meier analysis including number at risk of patients stratified into high or low *IL-6*- and *STAT3* mRNA expression predicting biochemical recurrence (BCR) of the Taylor data set³⁵. (c) Distribution of *STAT3* and p14^{ARF} protein expression with low (≤ 7) or high (8–10) GSC in tumour specimens from men diagnosed with PCa. (d) Fisher's exact test of data shown in c and correlation of *STAT3* to p14^{ARF} expression. (e) Kaplan-Meier analysis of BCR-free survival ratio based on *STAT3* protein expression in a panel of 204 PCa patients. (f) Kaplan-Meier analysis of BCR-free survival ratio based on p14^{ARF} protein expression in a panel of 204 PCa patients. (g) Co-expression analyses of BCR-free survival of *STAT3* and p14^{ARF}. (h) Univariate and multivariate analyses of GSC, *STAT3* or p14^{ARF} protein levels. Data from a,b,e,f and g were analysed by log-rank test.

signature of aggressive tumours, including *PTEN*, *SMAD4*, *CCND1* and *SPP1* (ref. 16), determination of *STAT3* and *ARF* expression could significantly improve the selection of patients with high risk PCa for personalized anti-cancer treatment.

We have uncovered a paradigm shift in understanding the key function of *STAT3* in tumorigenicity and metastatic progression in PCa. Therefore, our results call for cautious use of anti-*IL-6*-*STAT3* signalling blockers in the treatment of PCa as this may turn low-grade tumours into highly malignant cancers by loss of senescence controlled by the *STAT3*-*ARF* axis. As *IL-6*/*STAT3* signalling blockers are successful in the treatment of chronic inflammatory or autoimmune diseases, their influence on PCa development needs to be carefully evaluated in future studies. Reactivating the *IL-6*/*STAT3*/*ARF*-dependent senescence pathway⁵⁷ might be a promising strategy for PCa therapy via downregulation of *Mdm2* (ref. 58) or *p53* induction⁵⁹. Alternatively, triggering *ARF*-*p53*-independent cellular senescence by a small molecule inhibitor⁶⁰, could be beneficial for PCa patients in whom other therapies have failed.

Methods

Generation of transgenic mice. *Pten*^{loxP/loxP} mice crossed with male *PB-Cre4* transgenic mice were generated as described previously^{13,61}. To generate prostate-specific deletion of *Pten* and *IL-6*, we took advantage of *IL-6*^{-/-} mice³⁰. In a similar strategy, mice carrying *Stat3*^{loxP/loxP} were maintained and crossed with *PB-Cre4 Pten*^{loxP/loxP} transgenic mice. All mice were maintained on a C57BL/6 and Sv/129 mixed genetic background. Animal experiments were reviewed and approved by the Austrian ministry authorities and conducted according to relevant regulatory standards (BMWF-66.009/0281-1/3b/2012).

Immunohistochemistry and histological analysis. Immunohistochemistry and haematoxylin/eosin staining was performed with formalin-fixed paraffin-embedded (FFPE) tissue using standard protocols using consecutive sections. The following antibodies were used for immunohistochemistry: pY-Stat3 (1:80 dilution; Cell Signaling, #9145), pS-Stat3 (1:80; Cell Signaling, #9134), Stat3 (1:200 dilution; SCBT, sc-7179), p-Akt (1:80 dilution; Cell Signaling, #4060), Akt (1:100 dilution; Cell Signaling, #4691), p53 (1:50 dilution; Calbiochem, pAb421), p19^{ARF} (1:200 dilution; Abcam, ab-80), p14^{ARF} (1:100 dilution; SCBT, sc-8340), p21 (1:100 dilution; SCBT, sc-397), PML (1:100 dilution; SCBT, sc-966), Ki-67 (1:1,000 dilution; Novocastra; NCL-KI-67-P) and Cleaved Caspase 3 (1:200 dilution; Cell Signaling, #9661) and ISG15 (1:30; Abcam, 131119), AR (1:300; SCBT, sc-816). Staining for SA- β -Gal activity was performed according to the manufacturer's protocol (Cell Signaling,




Figure 8 | Loss of STAT3 and ARF in metastases of PCa patients. (a) Three representative images of PTEN expression determined by IHC analyses in matched patient samples with primary and metastatic PCa ($n = 5$). Scale bars, 100 μm . (b) Representative IHC images of STAT3 and p14^{ARF} expression from primary ($n = 41$) and metastatic ($n = 23$) PCa samples. Scale bars, 100 μm . (c,d) STAT3 and p14^{ARF} staining intensity ranging from undetectable (Negative) to maximal expression levels (+++) in cohorts of primary and metastatic PCa. (e) Graphical representation of *TP53*, *PTEN*, *STAT3* and *CDKN2A* mutations in 529 patients with primary PCa⁷¹. (f) Graphical representation of *TP53*, *PTEN*, *STAT3*, *CDKN2A* deletions in 14 metastatic PCa⁵⁵. Data were processed by Affymetrix Genome-Wide Human SNP Array 6.0. (g) Graphic representation of gene deletion analysis of *TP53*, *PTEN*, *STAT3* and *CDKN2A* in an independent data set of 37 metastatic PCa samples³⁵.

#9860). We used PTEN⁶³ and AR (1:250; DAKO, AR441)⁶⁴ antibodies validated for FFPE IHC. The STAT3 antibody was validated using SW620 colon cancer xenografts with shRNA-mediated knockdown (Supplementary Fig. 9b). The specificity of p14^{ARF} antibody was validated using the human melanoma cell lines⁶⁵ VM-28 (WT for p14^{ARF}) and VM-7 (deletion at the p14^{ARF} locus).

All images were taken with a Zeiss AxioImager Z1, and quantification was performed with HistoQuest (TissueGnostics GmbH, Vienna, Austria, www.tissuegnostics.com) as described in detail in (ref. 36). In brief, haematoxylin staining was used for cell identification. The range of intensities of the master marker (haematoxylin) and the immunohistochemical stainings were set by

autodetection of the software. All images were analysed with the identical settings after adjustments. The results are visualized in dot plot scattergrams and/or histograms. Cut-offs (to differentiate between positive and negative cells) and gates (to accentuate between cell populations) were set in the dot blots. For statistical analysis, the raw data were imported into GraphPad Prism 6 (GraphPad Software), analysed for significance and processed for data output. All images were taken with the same exposure time, signal amplification and objectives.

Western blot analysis. For protein expression analysis by western blot, frozen tissue samples and cell lysates were prepared as described¹⁶. Blots were blocked with 5% BSA or 5% non-fat dry milk in 1 × TBS/0.1% Tween-20 for 1 h and incubated with the primary antibody overnight at 4 °C. Primary antibodies were reactive to pY-Stat3 (1:500 dilution), pS-Stat3 (1:1,000 dilution), Stat3 (1:1,000 dilution; Cell Signaling, #9132), p19^{ARF} (1:1,000 dilution), p53 (1:1,000 dilution; Cell Signaling, #2524), p21 (1:500 dilution), β-actin (1:5,000 dilution; Sigma-Aldrich, A5316), p-Akt (1:1,000 dilution), Akt (1:2,000 dilution), AR (1:1,000 dilution), GAPDH (1:5,000 dilution; Cell Signaling, #2118), Pan-Cytokeratin (1,000 dilution; Abcam, Ab6401), Mdm2 (1:500 dilution; Millipore, 04-1530), PML (1:500 dilution; Millipore, MAB3738) and GAPDH (1:25,000; Trevigen, 2275-PC-100). Supplementary Figures 15–19 show uncropped immunoblots.

RNA and qRT-PCR. Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer's instructions. For quantitative reverse transcription PCR (qRT-PCR) analysis, 1 µg of total RNA was reverse transcribed to cDNA using the Transcriptor First-Strand cDNA Synthesis kit (Fermentas). qRT-PCR was performed in triplicate with aa MxPro3000 and SYBR GreenERqPCR mix (Invitrogen). Real-time monitoring of PCR amplification was performed using the LightCycler 480 detection system (Roche). The relative amount of specific mRNA was normalized to β-actin in each sample. Primer pairs are listed in Supplementary Table 3.

Cell culture. Primary WT and *Stat3*-null MEF were isolated by trypsin treatment of individual littermate E13.5 embryos from a cross of *Stat3*^{+/-} heterozygous mice. *Stat3*^{+/-} mice were generated from conditional *Stat3*^{+/-} mice⁶⁶ by deletion of the conditional allele *in vivo* using *Mox2-Cre*. Cells were amplified and used in experiments starting at passage 2. *Stat3*^{-/-} MEFs were grown in DMEM supplemented with 10% FBS, 2 mM L-Glutamine, 0.1 mM NEAA, 20 mM HEPES and pen/strep using standard techniques. *Stat3*^{Cl+} and *Stat3*^{ClC} MEFs were generously provided by Valeria Poli²⁸. For *in vitro* cultures LNCaP, RWPE-1 and PC3 were cultured under standard conditions.

Generation of primary mouse prostate cell lines. Dissected prostate tissue from WT and *Pten*^{pc-/-} mice at 19 weeks of age was cut into pieces of 0.2 mm, plated in tissue culture dishes coated with type I collagen (BD Pharmingen) and supplied with a minimal amount of epithelial growth medium containing 1% FBS serum. After 24 and 48 h, more medium was added. After an additional 24–72 h, cells began to grow out from the prostate tissue. Clean epithelial cell lines were obtained by removing the unwanted cell type with a cell scraper or pipette tip. Cells were passaged using Accutase (PAA, L11-00). For the generation of cell lines, cells were passaged until they survived crisis and only cells with typical epithelial morphology were maintained. WT and *Pten*^{pc-/-} prostate cell lines were established and maintained in DMEM/F12 (Invitrogen, 3133095) plus 10% foetal bovine serum (PAA, A15-101), 25 mg ml⁻¹ bovine pituitary extract (Invitrogen, 13028014), 5 mg ml⁻¹ EGF (Peprotech, 315-09), insulin/transferrin/selenite (Invitrogen, 41400-045), pen/strep (PAA, 30-002-CI), cholera toxin (Sigma-Aldrich, C8052-5MG) and ciprofloxacin (Sigma-Aldrich, 17580-5G). Prostate tumour epithelial cell lines expressed the epithelial marker Pan-Cytokeratin detected by immunofluorescence and western blot analysis. *Pten* deletion was confirmed by PCR and western blot analysis.

Human tissue microarray. The human tissue arrays representing a panel of 204 patient samples were obtained from the Institute of Pathology, Tuebingen, Germany and from the Clinical Institute of Pathology (CIP) of the Medical University of Vienna (MUW), Vienna, Austria. The cohort contains tumour material from PCa patients who consecutively underwent radical prostatectomy at the University Hospital of Tuebingen or the University Hospital of the MUW. Each PCa specimen was represented by two cores on tissue microarrays (TMA). From the CIP of the MUW, we furthermore obtained 41 PCa and 23 metastasis FFPE patient samples. In addition, we include FFPE material from 67 matched patient samples with PIN and PCa (GSC ≤ 7), as well as 7 matched patient samples with primary PCa and PCa metastases, all from the CIP, MUW. The FFPE tissue blocks were sectioned as 3-µm-thick sections mounted on slides and stained with haematoxylin and eosin. Subsequently, the area of cancer was marked by a pathologist (S.P.). Cores, each of up to 0.6 mm in diameter, were taken from the corresponding donor block and placed into a TMA recipient block using a semiautomatic tissue arrayer (Beecher Instruments). Tissue sections (3-µm thick) were placed onto superfrost slides. IBM SPSS Statistics 20 (IBM) was used for statistical analysis. For determination of time to BCR, which is defined by an increase to > 0.2 ng ml⁻¹ PSA in serum, a log-rank (Mantel–Cox) test was used to test significance. The

hazard ratio and its confidence interval were calculated using the Mantel–Haenszel method. All the human samples for TMA and their use in this study were approved by the Research Ethics Committee of the Medical University Vienna, Austria (1753/2014) and by the Research Ethics Committee for Germany (395/2008BO1) (Bonn, Germany).

Statistical analyses. Data were analysed using GraphPad Prism 6 software. For comparing two groups unpaired Students *t*-test and for comparing more than two groups Tukey's *post hoc* test was used. Fisher's exact test was employed when differences in distributions within groups were monitored. For Kaplan–Meier analysis and log-rank statistical evaluation of time to BCR, as well as evaluation of prognostic power in univariate and multivariate analysis, we used the IBM SPSS version 22 programme. To analyse Affymetrix SNP Chip 6.0 primary data, we used the AGCCytoScan Software together with the Chromosome Analysis Suite 3.0 (both Affymetrix), and deletions > 200 kb were considered significant. For analysis of mutations in primary PCa, we used the ICGC (www.icgc.org).

ELISA. For the detection of soluble sIL-6R in sera of mice, the samples were diluted 1:15 in 1% BSA–PBS. The ELISA was performed as described⁶⁷. In brief, microtiter plates (Greiner Microtron) were coated with anti-murine IL-6-R pAb AF1830 (0.8 µg ml⁻¹; R&D Systems) in PBS. After blocking, 100 µl aliquots of cell lysates or culture supernatants were added. IL-6R bound to the plate was detected by biotinylated goat anti-mouse IL-6-R pAb BAF1830 (working concentration, 0.2 µg ml⁻¹; R&D Systems) followed by streptavidin–horseradish peroxidase (R&D Systems). The enzymatic reaction was performed with soluble peroxidase substrate (BM blue POD from Roche) at 37 °C and the absorbance was read at 450 nm on a SLT Rainbow plate reader (Tecan). For the detection of murine IL-6 in sera of mice, the samples were diluted 1:3 with 1% BSA–PBS.

References

- Jemal, A. *et al.* Global cancer statistics. *CA Cancer J. Clin.* **61**, 69–90 (2011).
- Cooperberg, M. R., Broering, J. M., Kantoff, P. W. & Carroll, P. R. Contemporary trends in low risk prostate cancer: risk assessment and treatment. *J. Urol.* **178**, S14–S19 (2007).
- Dimakakos, A., Armakolas, A. & Koutsilieris, M. Novel tools for prostate cancer prognosis, diagnosis, and follow-up. *Biomed. Res. Int.* **2014**, 890697 (2014).
- Ost, P. *et al.* Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. *Prostate* **74**, 297–305 (2014).
- Draisma, G. *et al.* Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. *J. Natl. Cancer Inst.* **101**, 374–383 (2009).
- Jarnicki, A., Putoczki, T. & Ernst, M. Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? *Cell Div.* **5**, 14 (2010).
- Mora, L. B. *et al.* Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signalling induces apoptosis of prostate cancer cells. *Cancer Res.* **62**, 6659–6666 (2002).
- Culig, Z., Steiner, H., Bartsch, G. & Hobisch, A. Interleukin-6 regulation of prostate cancer cell growth. *J. Cell Biochem.* **95**, 497–505 (2005).
- Fizazi, K. *et al.* Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. *Eur. J. Cancer* **48**, 85–93 (2012).
- Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. *Nat. Rev. Mol. Cell Biol.* **13**, 283–296 (2012).
- Chen, Z. *et al.* Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature* **436**, 725–730 (2005).
- de la Iglesia, N. *et al.* Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. *Genes Dev.* **22**, 449–462 (2008).
- Wu, X. *et al.* Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech. Dev.* **101**, 61–69 (2001).
- Becker, C. *et al.* TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signalling. *Immunity* **21**, 491–501 (2004).
- Fukuda, A. *et al.* Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. *Cancer Cell* **19**, 441–455 (2011).
- Ding, Z. *et al.* SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. *Nature* **470**, 269–273 (2011).
- Trotman, L. C. *et al.* Pten dose dictates cancer progression in the prostate. *PLoS Biol.* **1**, E59 (2003).
- Gaggioli, C. *et al.* Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. *Nat. Cell Biol.* **9**, 1392–1400 (2007).
- Kuilman, T. *et al.* Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. *Cell* **133**, 1019–1031 (2008).
- Collado, M. *et al.* Tumour biology: senescence in premalignant tumours. *Nature* **436**, 642 (2005).

21. Zhou, B. P. *et al.* HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. *Nat. Cell Biol.* **3**, 973–982 (2001).
22. Roninson, I. B. Tumor cell senescence in cancer treatment. *Cancer Res.* **63**, 2705–2715 (2003).
23. Forsys, J. T. *et al.* ARF and p53 coordinate tumor suppression of an oncogenic IFN-beta-STAT1-IRF1 signalling axis. *Cell Rep.* **7**, 514–526 (2014).
24. Kiessling, A. *et al.* Expression, regulation and function of the ISGylation system in prostate cancer. *Oncogene* **28**, 2606–2620 (2009).
25. Hobisch, A. *et al.* Distant metastases from prostatic carcinoma express androgen receptor protein. *Cancer Res.* **55**, 3068–3072 (1995).
26. Freeman, D. J. *et al.* PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. *Cancer Cell* **3**, 117–130 (2003).
27. Yang, E., Lerner, L., Besser, D. & Darnell, Jr J. E. Independent and cooperative activation of chromosomal c-fos promoter by STAT3. *J. Biol. Chem.* **278**, 15794–15799 (2003).
28. Barbieri, I. *et al.* Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. *Cancer Res.* **70**, 2558–2567 (2010).
29. Riva, A. The MAPPER2 Database: a multi-genome catalog of putative transcription factor binding sites. *Nucleic Acids Res.* **40**, D155–D161 (2012).
30. Kopf, M. *et al.* Impaired immune and acute-phase responses in interleukin-6-deficient mice. *Nature* **368**, 339–342 (1994).
31. Dunn, G. P., Sheehan, K. C., Old, L. J. & Schreiber, R. D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. *Cancer Res.* **65**, 3447–3453 (2005).
32. Hedvat, M. *et al.* The JAK2 inhibitor AZD1480 potently blocks Stat3 signalling and oncogenesis in solid tumors. *Cancer Cell* **16**, 487–497 (2009).
33. Lou, W., Ni, Z., Dyer, K., Tweardy, D. J. & Gao, A. C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signalling pathway. *Prostate* **42**, 239–242 (2000).
34. Ichiba, M., Nakajima, K., Yamanaka, Y., Kiuchi, N. & Hirano, T. Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. *J. Biol. Chem.* **273**, 6132–6138 (1998).
35. Taylor, B. S. *et al.* Integrative genomic profiling of human prostate cancer. *Cancer Cell* **18**, 11–22 (2010).
36. Schleuderer, M. *et al.* Reliable quantification of protein expression and cellular localization in histological sections. *PLoS ONE* **9**, e100822 (2014).
37. Zhang, X. *et al.* Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. *PLoS ONE* **6**, e27970 (2011).
38. Grasso, C. S. *et al.* The mutational landscape of lethal castration-resistant prostate cancer. *Nature* **487**, 239–243 (2012).
39. Goh, L. K. *et al.* Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. *PLoS ONE* **9**, e91666 (2014).
40. Spiotto, M. T. & Chung, T. D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. *Prostate* **42**, 186–195 (2000).
41. Toso, A. *et al.* Enhancing chemotherapy efficacy in pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. *Cell Rep.* **9**, 75–89 (2014).
42. Kang, T. W. *et al.* Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. *Nature* **479**, 547–551 (2011).
43. Rodier, F. & Campisi, J. Four faces of cellular senescence. *J. Cell Biol.* **192**, 547–556 (2011).
44. Grabner, B. *et al.* Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. *Nat. Commun.* **6**, 6285 (2015).
45. Nakashima, J. *et al.* Serum interleukin 6 as a prognostic factor in patients with prostate cancer. *Clin. Cancer Res.* **6**, 2702–2706 (2000).
46. Hudes, G. *et al.* A phase I study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. *Invest New Drugs* **31**, 669–676 (2013).
47. Gray-Schopfer, V. C. *et al.* Cellular senescence in naevi and immortalisation in melanoma: a role for p16? *Br. J. Cancer* **95**, 496–505 (2006).
48. Sherr, C. J. Divorcing ARF and p53: an unsettled case. *Nat. Rev. Cancer* **6**, 663–673 (2006).
49. Chen, Z. *et al.* Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. *Sci. Signal.* **2**, ra44 (2009).
50. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H. & Sherr, C. J. Tumor spectrum in ARF-deficient mice. *Cancer Res.* **59**, 2217–2222 (1999).
51. McCall, P., Witton, C. J., Grimsley, S., Nielsen, K. V. & Edwards, J. Is PTEN loss associated with clinical outcome measures in human prostate cancer? *Br. J. Cancer* **99**, 1296–1301 (2008).
52. Lotan, T. L. *et al.* PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. *Clin. Cancer Res.* **17**, 6563–6573 (2011).
53. Suzuki, H. *et al.* Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. *Cancer Res.* **58**, 204–209 (1998).
54. Liu, W. *et al.* Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat. Med.* **15**, 559–565 (2009).
55. Michaloglou, C. *et al.* BRAFE600-associated senescence-like cell cycle arrest of human naevi. *Nature* **436**, 720–724 (2005).
56. Hubackova, S. *et al.* Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signalling. *Cell Cycle* **9**, 3085–3099 (2010).
57. Chang, Y. S. *et al.* Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. *Proc. Natl Acad. Sci. USA* **110**, E3445–E3454 (2013).
58. Wade, M., Li, Y. C. & Wahl, G. M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. *Nat. Rev. Cancer* **13**, 83–96 (2013).
59. Soucy, T. A. *et al.* An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. *Nature* **458**, 732–736 (2009).
60. Carver, B. S. *et al.* Reciprocal feedback regulation of PI3K and androgen receptor signalling in PTEN-deficient prostate cancer. *Cancer Cell* **19**, 575–586 (2011).
61. Alonzi, T. *et al.* Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver. *Mol. Cell Biol.* **21**, 1621–1632 (2001).
62. Li, N. *et al.* Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. *Genes Dev.* **29**, 157–170 (2015).
63. Kozakowski, N. *et al.* Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mTOR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment. *Target Oncol.* **9**, 359–366 (2014).
64. Mathieu, V. *et al.* Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation. *Oncotarget* **3**, 399–413 (2012).
65. Lee, C. K. *et al.* STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. *Immunity* **17**, 63–72 (2002).
66. Chalaris, A. *et al.* Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signalling function of neutrophils. *Blood* **110**, 1748–1755 (2007).
67. Chen, Y. *et al.* ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. *Nat. Med.* **19**, 1023–1029 (2013).
68. Lang, R. *et al.* SOCS3 regulates the plasticity of gp130 signalling. *Nat. Immunol.* **4**, 546–550 (2003).
69. Basham, B. *et al.* In vivo identification of novel STAT5 target genes. *Nucleic Acids Res.* **36**, 3802–3818 (2008).
70. Hudson, T. J. *et al.* International network of cancer genome projects. *Nature* **464**, 993–998 (2010).

Acknowledgements

L.K. and J.P. are supported by FWF, P26011 and the Genome Research-Austria project 'Inflammobiota' grants. H.D. is supported by the Herzfelder Family Foundation and the Niederösterreich. Forschungs- und Bildungsges.m.b.H (nfb). R.M. is supported by grant SFB-F2807 and SFB-F4707 from the Austrian Science Fund (FWF); A.M. is supported by Infrastructure for biosciences-Strategic fund, SciLifeLab and Formas, Z.C. is supported by FWF, P24428; A.C. and S.R.-J. are supported by the Deutsche Forschungsgemeinschaft (Grant SFB 877, Project A1 and the Cluster of Excellence–'Inflammation at Interfaces'). A.S. is supported by the European FP7 Marie-Curie Initial Training Network HEM_ID. Work of the Abergler lab was supported by the Austrian Science Fund FWF (Projects P25629 and W1213), the European FP7 Marie-Curie Initial Training Network HEALING and the priority program Biosciences and Health of the Paris-Lodron University of Salzburg. V.P. is supported by the Italian Association for Cancer Research (AIRC, No IG13009). R.K. and S.M.W. are supported by the McClay Foundation and the Movember Centre of Excellence (PC-UK and Movember). O.H. K. is supported by Wilhelm-Sander Stiftung (grant 2010.078.2), Deutsche Krebshilfe (grant 110909), Deutsche Forschungsgemeinschaft (grant KR2291/4-1) and intramural funding from the University Medical Center Mainz. G.E. is supported by FWF, P27616. T.M. and S.D.T. are supported by Leukaemia and Lymphoma Research. We thank Markus Mair, Harini Nivarthi, Tina Brachett and Jelena Marjanovic for their excellent technical support. We also thank Gerardo Ferbeyre for providing the PML antibody. We thank Andrew Pospisilik for critically reading the manuscript.

Author contributions

J.P. and L.K. conceived and designed the research; J.P., M. Schleuderer, A.M., W.G., F.A., R.K., S.M.W., A.C., I.J.M., M.R.H., C.U., N.P., O.A., J.K.B., G.E., V.P., W.M., R.E., F.F., D.E.L., T.J., A.S., F.G., M. Susani, M.B., S.P., M.H., P.M., A.H., M. Scharpf, O.H.K., T.M., S.D.T., H.D. and L.K. performed the research; S.R.-J., O.M., Z.C., J.P., L.K., M. Schleuderer and H.D. analysed the data; H.E. was involved in manuscript preparation; J.P., L.K. and H.D. wrote the manuscript; all authors reviewed and approved the manuscript for publication.

Additional information

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Pencik, J. *et al.* STAT3 regulated ARF expression suppresses prostate cancer metastasis. *Nat. Commun.* 6:7736 doi: 10.1038/ncomms8736 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>